Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High dose, low frequency parenteral gold administration.

W L Norton, R J Donnelly

    The Journal of Rheumatology
    |June 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Toxic Immunoglobulin Light Chain Autoantibodies are Associated with a Cluster of Severe Complications in Older Adult Type 2 Diabetes.

    Journal of endocrinology and diabetes·2018
    Same author

    Temperature structure functions in the Bolgiano regime of thermal convection.

    Physical review. E, Statistical, nonlinear, and soft matter physics·2002
    Same author

    The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by substance P: an understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell.

    Journal of neuroimmunology·2001
    Same author

    Congenital ovine neuronal ceroid lipofuscinosis--a cathepsin D deficiency with increased levels of the inactive enzyme.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2001
    Same author

    Four regimes of decaying grid turbulence in a finite channel.

    Physical review letters·2000
    Same author

    A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration.

    The EMBO journal·2000

    Aurothioglucose treatment showed significant improvements in rheumatoid arthritis patients, with most experiencing reduced joint swelling and increased grip strength. Further research into optimized gold administration strategies is recommended for better patient outcomes.

    Area of Science:

    • Rheumatology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
    • Gold compounds, such as aurothioglucose, have been used as disease-modifying antirheumatic drugs (DMARDs).
    • Optimizing the administration of gold therapy is crucial for maximizing efficacy and patient benefit.

    Purpose of the Study:

    • To evaluate the efficacy of a specific dosage regimen of aurothioglucose in patients with rheumatoid arthritis.
    • To assess the impact of aurothioglucose treatment on clinical and laboratory parameters of RA.
    • To explore potential improvements in gold administration strategies.

    Main Methods:

    • A cohort of 30 patients with rheumatoid arthritis received aurothioglucose at intervals of approximately 4 weeks, with dosages up to 200 mg.

    Related Experiment Videos

  • Clinical assessments included grip strength and the number of swollen joints.
  • Laboratory markers, such as erythrocyte sedimentation rate (ESR), were monitored.

    • Main Results:

    • A moderate to major clinical improvement was observed in 20 out of 30 patients.
    • Significant reductions in mean ESR (from 46 to 26 mm/h) and mean swollen joints (from 10.9 to 3.3) were recorded.
    • Mean grip strength (best hand) increased substantially from 99 to 179 mm Hg.
    • Peak therapeutic effects were achieved at a mean cumulative dose of 649 mg and after approximately 18 weeks of treatment.

    Conclusions:

    • The tested dosage regimen of aurothioglucose demonstrated significant efficacy in improving clinical and laboratory parameters in RA patients.
    • The findings suggest that current gold administration protocols may not be optimal.
    • Further investigation into developing more efficient strategies for aurothioglucose administration is warranted to enhance treatment outcomes in rheumatoid arthritis.